Uptake of a randomized breast cancer prevention trial comparing letrozole to placebo in BRCA1/2 mutations carriers: the LIBER trial

@article{Pujol2011UptakeOA,
  title={Uptake of a randomized breast cancer prevention trial comparing letrozole to placebo in BRCA1/2 mutations carriers: the LIBER trial},
  author={Pascal Pujol and Christine Lasset and Pascaline Berthet and Catherine Dugast and Suzette Delaloge and Jon D. Fricker and Isabelle Tennevet and Nathalie Chabbert-Buffet and Pascale This and Karen Baudry and J{\'e}r{\^o}me Lemonnier and Lise Roca and Sylvie Mijonnet and Paul Gesta and Jean Chiesa and H{\'e}l{\'e}ne Dreyfus and Philippe Vennin and Capucine Delnatte and Yves Jean Bignon and Alain Lortholary and Fabienne Prieur and Laurence Gladieff and Anne Lesur and Krishna Bentley Clough and Catherine Nogu{\'e}s and Andrew Martin},
  journal={Familial Cancer},
  year={2011},
  volume={11},
  pages={77-84}
}
Women with germline BRCA1 or BRCA2 (BRCA1/2) mutations are considered as an extreme risk population for developing breast cancer. Prophylactic mastectomy provides a valid option to reduce such risk, impacting however, the quality of life. Medical prevention by aromatase inhibitor that has also recently shown to have preventive effect may thus be considered as an alternative. LIBER is an ongoing double-blind, randomized phase III trial to evaluate the efficacy of 5-year letrozole versus placebo… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 11 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 40 references

Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen

  • M Dowsett
  • J Clin Oncol
  • 2010
2 Excerpts

Similar Papers

Loading similar papers…